Literature DB >> 33232306

Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model.

Amélie M Borie1, Yann Dromard1, Gilles Guillon1, Aleksandra Olma2, Maurice Manning2, Françoise Muscatelli3, Michel G Desarménien1, Freddy Jeanneteau1.   

Abstract

Intellectual and social disabilities are common comorbidities in adolescents and adults with MAGE family member L2 (MAGEL2) gene deficiency characterizing the Prader-Willi and Schaaf-Yang neurodevelopmental syndromes. The cellular and molecular mechanisms underlying the risk for autism in these syndromes are not understood. We asked whether vasopressin functions are altered by MAGEL2 deficiency and whether a treatment with vasopressin could alleviate the disabilities of social behavior. We used Magel2-knockout mice (adult males) combined with optogenetic or pharmacological tools to characterize disease modifications in the vasopressinergic brain system and monitor its impact on neurophysiological and behavioral functions. We found that the activation of vasopressin neurons and projections in the lateral septum were inappropriate for performing a social habituation/discrimination task. Mechanistically, the lack of vasopressin impeded the deactivation of somatostatin neurons in the lateral septum, which predicted social discrimination deficits. Correction of vasopressin septal content by administration or optogenetic stimulation of projecting axons suppressed the activity of somatostatin neurons and ameliorated social behavior. This preclinical study identified vasopressin in the lateral septum as a key factor in the pathophysiology of Magel2-related neurodevelopmental syndromes.

Entities:  

Keywords:  Mouse models; Neuroendocrine regulation; Neuroscience; Psychiatric diseases

Year:  2021        PMID: 33232306      PMCID: PMC7810497          DOI: 10.1172/JCI144450

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene.

Authors:  Fabienne Schaller; Françoise Watrin; Rachel Sturny; Annick Massacrier; Pierre Szepetowski; Françoise Muscatelli
Journal:  Hum Mol Genet       Date:  2010-09-28       Impact factor: 6.150

2.  A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.

Authors:  Federico Bolognani; Marta Del Valle Rubido; Lisa Squassante; Christoph Wandel; Michael Derks; Lorraine Murtagh; Jeff Sevigny; Omar Khwaja; Daniel Umbricht; Paulo Fontoura
Journal:  Sci Transl Med       Date:  2019-05-01       Impact factor: 17.956

3.  The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome.

Authors:  Maïthé Tauber; Kader Boulanouar; Gwenaelle Diene; Sophie Çabal-Berthoumieu; Virginie Ehlinger; Pascale Fichaux-Bourin; Catherine Molinas; Sandy Faye; Marion Valette; Jeanne Pourrinet; Catie Cessans; Sylvie Viaux-Sauvelon; Céline Bascoul; Antoine Guedeney; Patric Delhanty; Vincent Geenen; Henri Martens; Françoise Muscatelli; David Cohen; Angèle Consoli; Pierre Payoux; Catherine Arnaud; Jean-Pierre Salles
Journal:  Pediatrics       Date:  2017-02       Impact factor: 7.124

4.  Distinct Inhibitory Circuits Orchestrate Cortical beta and gamma Band Oscillations.

Authors:  Guang Chen; Yuan Zhang; Xiang Li; Xiaochen Zhao; Qian Ye; Yingxi Lin; Huizhong W Tao; Malte J Rasch; Xiaohui Zhang
Journal:  Neuron       Date:  2017-12-20       Impact factor: 17.173

Review 5.  Oxytocin and Animal Models for Autism Spectrum Disorder.

Authors:  Shlomo Wagner; Hala Harony-Nicolas
Journal:  Curr Top Behav Neurosci       Date:  2018

6.  Somatostatin interneurons in the prefrontal cortex control affective state discrimination in mice.

Authors:  Diego Scheggia; Francesca Managò; Federica Maltese; Stefania Bruni; Marco Nigro; Daniel Dautan; Patrick Latuske; Gabriella Contarini; Marta Gomez-Gonzalo; Linda Maria Requie; Valentina Ferretti; Giulia Castellani; Daniele Mauro; Alessandra Bonavia; Giorgio Carmignoto; Ofer Yizhar; Francesco Papaleo
Journal:  Nat Neurosci       Date:  2019-12-16       Impact factor: 24.884

Review 7.  The Current Status of Somatostatin-Interneurons in Inhibitory Control of Brain Function and Plasticity.

Authors:  Isabelle Scheyltjens; Lutgarde Arckens
Journal:  Neural Plast       Date:  2016-06-14       Impact factor: 3.599

8.  Dorsolateral septum somatostatin interneurons gate mobility to calibrate context-specific behavioral fear responses.

Authors:  Yuan Gao; Michael TaeWoo Kim; Antoine Besnard; Hannah Twarkowski; Alexander Keith Reed; Tomer Langberg; Wendy Feng; Xiangmin Xu; Dieter Saur; Larry S Zweifel; Ian Davison; Amar Sahay
Journal:  Nat Neurosci       Date:  2019-02-04       Impact factor: 24.884

Review 9.  Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders.

Authors:  M A Lebow; A Chen
Journal:  Mol Psychiatry       Date:  2016-02-16       Impact factor: 13.437

10.  Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production.

Authors:  Helen Chen; A Kaitlyn Victor; Jonathon Klein; Klementina Fon Tacer; Derek Jc Tai; Celine de Esch; Alexander Nuttle; Jamshid Temirov; Lisa C Burnett; Michael Rosenbaum; Yiying Zhang; Li Ding; James J Moresco; Jolene K Diedrich; John R Yates; Heather S Tillman; Rudolph L Leibel; Michael E Talkowski; Daniel D Billadeau; Lawrence T Reiter; Patrick Ryan Potts
Journal:  JCI Insight       Date:  2020-09-03
View more
  5 in total

Review 1.  Oxytocin, Vasopressin, and Social Behavior: From Neural Circuits to Clinical Opportunities.

Authors:  Nicole Rigney; Geert J de Vries; Aras Petrulis; Larry J Young
Journal:  Endocrinology       Date:  2022-09-01       Impact factor: 5.051

Review 2.  Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.

Authors:  Valeska Cid-Jofré; Macarena Moreno; Miguel Reyes-Parada; Georgina M Renard
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

3.  The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment.

Authors:  Bo Zhou; Xiaoli Zheng; Yunhua Chen; Xuehui Yan; Jinggang Peng; Yibu Liu; Yi Zhang; Lei Tang; Min Wen
Journal:  Front Neurosci       Date:  2022-03-25       Impact factor: 4.677

4.  Natura Non Facit Saltus: The Adaptive Significance of Arginine Vasopressin in Human Affect, Cognition, and Behavior.

Authors:  Bernard Crespi; Tanya Procyshyn; Mika Mokkonen
Journal:  Front Behav Neurosci       Date:  2022-05-02       Impact factor: 3.558

5.  Phenotypic spectrum and mechanism analysis of Schaff Yang syndrome: A case report on new mutation of MAGEL2 gene.

Authors:  Yanjie Duan; Lu Liu; Xiujuan Zhang; Xiuyun Jiang; Jin Xu; Qingbo Guan
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.